CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity

CordenPharma, a prominent global Contract Development and Manufacturing Organization (CDMO), has announced its agreement to acquire AmbioPharm, a U.S.-headquartered peptide CDMO, for an undisclosed amount. The transaction, which was revealed on May 27, 2026, aims to enhance CordenPharma's peptide manufacturing capabilities and expand its global expertise in complex peptide active pharmaceutical ingredients (APIs). With facilities located in North Augusta, South Carolina, and Shanghai, China, AmbioPharm will significantly bolster CordenPharma's operational footprint in the peptide sector.

The acquisition of AmbioPharm is strategically aligned with CordenPharma's goal to strengthen its U.S. peptide manufacturing capabilities. By integrating AmbioPharm's facilities into its existing network, CordenPharma will enhance its capacity for U.S.-based peptide API supply, thereby providing customers with more flexible and reliable manufacturing options. The addition of AmbioPharm's North Augusta site, which focuses on the purification and lyophilization of peptide APIs, complements CordenPharma's existing capabilities in Colorado, allowing for a more robust offering for large-scale commercial peptide projects.

In addition to expanding U.S. capabilities, the acquisition allows CordenPharma to leverage AmbioPharm's Shanghai facility, which features advanced manufacturing technologies for clinical and commercial peptide supply. This integration will provide CordenPharma with significant upstream capacity across various synthesis methods, including Solid-Phase Peptide Synthesis (SPPS) and Liquid-Phase Peptide Synthesis (LPPS). By enhancing its global Peptides Platform, CordenPharma aims to offer comprehensive end-to-end support for peptide development and manufacturing, catering to the evolving needs of its clients in the pharmaceutical sector.

The broader implications of this acquisition reflect a significant trend in the peptide CDMO market, which is experiencing rapid growth due to increasing demand for complex peptide-based therapeutics. As the pharmaceutical industry continues to prioritize innovative drug development, CDMOs that can provide comprehensive manufacturing solutions are well-positioned for success. CordenPharma's strategic move to acquire AmbioPharm not only enhances its capabilities but also underscores the importance of geographic flexibility and operational scale in meeting the needs of global customers.

Overall, this acquisition marks a pivotal step in CordenPharma's growth trajectory, further solidifying its position as a leading partner in peptide manufacturing. As the market for peptide-based medicines expands, the integration of AmbioPharm's capabilities is expected to yield significant long-term growth opportunities for CordenPharma, enabling it to better serve its clients and contribute to the advancement of peptide therapeutics worldwide.